A carregar...
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
PURPOSE: In a phase I study, the combination of gemcitabine and imatinib was well tolerated with broad anticancer activity. This phase I trial evaluated the triplet of docetaxel, gemcitabine and imatinib. EXPERIMENTAL DESIGN: Imatinib was administered at 400 mg daily on days 1–5, 8–12 and 15–19. Gem...
Na minha lista:
| Publicado no: | Invest New Drugs |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5300057/ https://ncbi.nlm.nih.gov/pubmed/20697775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9504-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|